Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study

To assess the effectiveness and safety of switching the antidepressant formulation from immediate-release (IR) to controlled-release (CR) paroxetine in patients with major depressive disorder (MDD). A total of 113 outpatients with MDD diagnosed according to the , Fourth Edition, Text Revision, and t...

Full description

Saved in:
Bibliographic Details
Published in:Neuropsychiatric disease and treatment 2018-01, Vol.14, p.955-966
Main Authors: Otsubo, Tempei, Watanabe, Yoshinori, Hongo, Seiji, Inoue, Mikichika, Akimoto, Kimiko, Murakami, Ken, Takahashi, Ryutaro, Kikuchi, Toshiaki
Format: Article
Language:English
Subjects:
antidepressant
Antidepressants
Anxiety
Care and treatment
Chi-square test
Comparative analysis
controlled-release paroxetine
Desvenlafaxine
Diagnosis
drug formulation
Escitalopram
Future predictions
Handbooks
Labels
Major depressive disorder
Mental depression
Mental disorders
Original Research
Paroxetine
Sleep
switching
Systematic review
Xerostomia
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To assess the effectiveness and safety of switching the antidepressant formulation from immediate-release (IR) to controlled-release (CR) paroxetine in patients with major depressive disorder (MDD). A total of 113 outpatients with MDD diagnosed according to the , Fourth Edition, Text Revision, and treated with a stable dose of IR paroxetine for at least 6 months were enrolled. Patients were then switched to CR paroxetine for 8 weeks. Effectiveness was evaluated by scores on the Himorogi Self-Rating Depression/Anxiety Scales (HSDS/HSAS) and the Clinical Global Impression - Severity (CGI-S). Safety was evaluated based on the reported adverse drug reactions (ADRs). Medication satisfaction and preference were assessed based on questionnaire responses using Likert-type scales. The overall patient HSDS/HSAS scores significantly improved after switching from IR to CR paroxetine (
ISSN:1176-6328
1178-2021
1178-2021
DOI:10.2147/NDT.S152985